Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking

Jeffrey Goldberger, Rod Passman

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.

Original languageEnglish (US)
Pages (from-to)2001-2005
Number of pages5
JournalJournal of the American College of Cardiology
Volume54
Issue number22
DOIs
StatePublished - Nov 24 2009
Externally publishedYes

Fingerprint

Implantable Defibrillators
Myocardial Infarction
Sudden Death
Therapeutics
Sudden Cardiac Death
Cause of Death
Randomized Controlled Trials
Survival

Keywords

  • implantable defibrillator
  • myocardial infarction
  • sudden death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking. / Goldberger, Jeffrey; Passman, Rod.

In: Journal of the American College of Cardiology, Vol. 54, No. 22, 24.11.2009, p. 2001-2005.

Research output: Contribution to journalReview article

@article{6e0ff5091f7e450eab4e778787b757e2,
title = "Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking",
abstract = "The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.",
keywords = "implantable defibrillator, myocardial infarction, sudden death",
author = "Jeffrey Goldberger and Rod Passman",
year = "2009",
month = "11",
day = "24",
doi = "10.1016/j.jacc.2009.08.018",
language = "English (US)",
volume = "54",
pages = "2001--2005",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "22",

}

TY - JOUR

T1 - Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking

AU - Goldberger, Jeffrey

AU - Passman, Rod

PY - 2009/11/24

Y1 - 2009/11/24

N2 - The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.

AB - The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.

KW - implantable defibrillator

KW - myocardial infarction

KW - sudden death

UR - http://www.scopus.com/inward/record.url?scp=71849085003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849085003&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2009.08.018

DO - 10.1016/j.jacc.2009.08.018

M3 - Review article

VL - 54

SP - 2001

EP - 2005

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 22

ER -